BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 21, 2015
 |  BioCentury  |  Finance

Flower power

Totting up Forbion's returns on CETP play Dezima after Amgen takeout

In three years, Forbion Capital Partners has turned a Japanese pharma's discarded cardiovascular asset into a return that could reach 50x. The key to the payday was the firm's conviction that prior failures of other cholesteryl ester transfer protein inhibitors were compound-specific.

Forbion formed Dezima Pharma B.V. in 2012 to develop TA-8995, a CETP inhibitor that the biotech licensed from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) for undisclosed terms (see BioCentury, Jan. 28, 2013).

Forbion and BioGeneration Ventures seeded Dezima in 2012 and invested in the company's $13 million series A round in 2013 along with New Science Ventures.


Read the full 523 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >